A decade of standardisation work was necessary to deliver a new set of international standards for the unambiguous identification of medicinal products in the regulatory process. The initiative, named "IDMP, Identification of Medicinal Products", was required to increase safety in the adverse event notification process. Regulators are now taking steps to implement IDMP.
It is necessary to clarify for the user community, including the regulators, that GS1 standards and IDMP complete each other. That was the driver for the adoption in the fall 2017 of a GS1 position paper which summarises the interactions between supply chain (GS1) and IDMP.
Read the position paper